Mawer Investment Management Ltd. Sells 8,150 Shares of Johnson & Johnson $JNJ

Mawer Investment Management Ltd. lessened its stake in Johnson & Johnson (NYSE:JNJ) by 2.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 401,662 shares of the company’s stock after selling 8,150 shares during the period. Mawer Investment Management Ltd.’s holdings in Johnson & Johnson were worth $74,476,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Evolution Wealth Management Inc. bought a new stake in Johnson & Johnson during the 2nd quarter worth about $27,000. Clayton Financial Group LLC acquired a new stake in shares of Johnson & Johnson during the 3rd quarter worth approximately $28,000. Semmax Financial Advisors Inc. grew its position in shares of Johnson & Johnson by 55.0% during the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after buying an additional 72 shares during the period. GFG Capital LLC bought a new stake in shares of Johnson & Johnson during the second quarter worth approximately $35,000. Finally, Signature Resources Capital Management LLC lifted its holdings in Johnson & Johnson by 262.9% in the third quarter. Signature Resources Capital Management LLC now owns 254 shares of the company’s stock valued at $47,000 after buying an additional 184 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have commented on JNJ shares. Sanford C. Bernstein upped their target price on shares of Johnson & Johnson from $208.00 to $225.00 and gave the company a “market perform” rating in a research report on Friday, January 23rd. Royal Bank Of Canada set a $240.00 price objective on Johnson & Johnson in a report on Wednesday, December 17th. Loop Capital set a $220.00 target price on Johnson & Johnson in a report on Tuesday, January 27th. Wolfe Research upped their price target on Johnson & Johnson from $225.00 to $240.00 and gave the company an “outperform” rating in a research note on Monday, January 5th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of Johnson & Johnson in a research note on Wednesday, January 28th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $233.05.

Johnson & Johnson Trading Up 1.6%

Shares of NYSE:JNJ opened at $230.82 on Tuesday. The firm has a market cap of $556.11 billion, a price-to-earnings ratio of 20.89, a PEG ratio of 2.21 and a beta of 0.35. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 12 month low of $141.50 and a 12 month high of $231.19. The company’s fifty day simple moving average is $211.21 and its 200 day simple moving average is $192.24.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, January 21st. The company reported $2.46 earnings per share (EPS) for the quarter, meeting the consensus estimate of $2.46. The firm had revenue of $24.56 billion for the quarter, compared to the consensus estimate of $24.14 billion. Johnson & Johnson had a return on equity of 33.34% and a net margin of 28.46%.The company’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same quarter last year, the business posted $2.04 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. As a group, research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a yield of 2.3%. Johnson & Johnson’s dividend payout ratio is 47.06%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.